Stocksigma LogoStocksigma Logo

Sun Pharma Announces Positive Two-Year LEQSELVI Data in Severe Alopecia Areata

Sun Pharma presented two-year open-label extension data for LEQSELVI (deuruxolitinib 8 mg BID) at the EADV Congress on 1st Oct'26, showing sustained

Sun Pharma Announces Positive Two-Year LEQSELVI Data in Severe Alopecia Areata

Sun Pharmaceutical Industries Ltd · Press Release · 01 Oct 2026, 11:16 pm

Sun Pharma Announces Positive Two-Year LEQSELVI Data in Severe Alopecia Areata Sun Pharma presented two-year open-label extension data for LEQSELVI (deuruxolitinib 8 mg BID) at the EADV Congress on 1st Oct'26, showing sustained efficacy and consistent safety in severe alopecia areata. Among baseline responders, 93.9% maintained response (SALT score ≤20) through Week 108. Of initial nonresponders achieving response at Week 52, 96.8% maintained efficacy through Week 108. Safety remained consistent with earlier trials, showing mostly mild-to-moderate adverse events and no deaths, thrombosis, or major adverse cardiovascular events at the FDA-approved dosage.

Original exchange filing (PDF)

More announcements from Sun Pharmaceutical Industries Ltd

All Sun Pharmaceutical Industries Ltd announcements